How a Mouth Bacterium Fuels Cancer Growth

A Microbe That Travels From Mouth to Tumor

The human mouth harbors hundreds of bacterial species, most of them harmless. One, however, has caught the attention of cancer researchers worldwide. Fusobacterium nucleatum — a rod-shaped anaerobe that thrives in dental plaque and inflamed gums — has been found enriched inside tumors far from the oral cavity, particularly in the colon and breast.

Scientists first noticed the connection about a decade ago, when genomic surveys of colorectal tumors kept turning up unusually high levels of F. nucleatum. Since then, studies published in Nature, Nature Communications, and the National Cancer Institute have mapped out how this single microbe can hijack the body's own pathways to accelerate cancer.

How It Reaches Distant Organs

F. nucleatum does not stay in the mouth. In people with periodontal (gum) disease, chronic inflammation allows the bacterium to enter the bloodstream — a process called bacteremia. Once circulating, it latches onto a sugar molecule called Gal-GalNAc that is displayed on the surface of many tumor cells. A bacterial protein called Fap2 acts as the key that fits this lock, guiding the microbe straight to cancerous tissue.

Researchers have confirmed this homing ability in animal models: when F. nucleatum was injected into the bloodstream of mice with mammary tumors, it selectively colonized the tumor tissue rather than healthy organs.

What It Does Inside a Tumor

Once embedded in a tumor, F. nucleatum promotes cancer through several mechanisms:

• DNA damage. The bacterium triggers double-strand DNA breaks and activates error-prone repair pathways, increasing the mutation rate in surrounding cells.
• Immune suppression. It reduces the accumulation of tumor-infiltrating T cells — the immune system's main cancer-fighting soldiers — effectively helping the tumor hide from immune surveillance.
• Accelerated growth. Its adhesin protein FadA binds to E-cadherin on cell surfaces, activating the beta-catenin signaling pathway that drives cell proliferation.
• Metastasis. F. nucleatum increases vascular permeability, making it easier for cancer cells to break free and spread to distant sites.

The BRCA1 Connection

Research from Johns Hopkins Medicine has revealed a particularly alarming interaction. Breast cells carrying BRCA1 mutations — already at elevated cancer risk — display higher levels of the Gal-GalNAc sugar on their surfaces. This makes them more vulnerable to bacterial colonization. In laboratory experiments, even brief exposure to F. nucleatum activated a protein called PKcs in BRCA1-mutant cells, which was associated with enhanced tumor migration, invasion, and resistance to chemotherapy.

The findings suggest that inherited genetic risk and bacterial infection may act as co-conspirators, together pushing cells toward malignancy faster than either factor alone.

Not All Strains Are Equal

A landmark 2024 study in Nature showed that F. nucleatum subspecies animalis splits into two distinct genetic clades. Only one — designated Fna C2 — dominates the colorectal cancer niche. People with colorectal cancer were roughly five times more likely to carry this specific clade in their stool than healthy individuals, suggesting that targeted diagnostics could one day distinguish dangerous strains from benign ones.

What This Means for Prevention

The research does not yet prove that F. nucleatum alone causes cancer — most evidence comes from animal models and tissue studies. But the implications are significant. Good oral hygiene and treatment of gum disease may reduce the bacterial load entering the bloodstream. In mouse models, antibiotic treatment reversed some of the tumor-promoting effects, hinting at future therapeutic strategies.

Scientists are now exploring whether screening for F. nucleatum in stool or blood could serve as an early biomarker for colorectal or breast cancer risk — a simple test that could flag danger long before a tumor becomes visible on a scan.